Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 2, 2006 (13 weeks)
Business Overview: Illumina develops and markets tools for large-scale genetic analysis, including genotyping and gene expression systems (BeadArray technology), oligonucleotides, and related services. The company operates in a single segment.
Key Financial Metrics
| Metric (in thousands) | Q1 2006 | Q1 2005 |
|---|---|---|
| Total Revenue | $29,102 | $15,148 |
| Net Loss | $(104) | $(1,235) |
| Operating Loss | $(541) | $(1,379) |
| Cash from Operations | $2,360 | $(3,325) |
| Cash and Equivalents (End of Period) | $49,044 | $52,953 |
| Total Assets | $112,526 | $100,610 |
| Total Debt (Current + Long-term) | $143 | $172 |
Margins:
- Gross Margin (Product & Service): 67% (Q1 2006) vs. 69% (Q1 2005).
- Gross Margin (Product only): 67% (Q1 2006) vs. 68% (Q1 2005).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 92% year-over-year to $29.1 million, driven by a 91% increase in product revenue and a 96% increase in service revenue. Product growth was fueled by the launch of the HumanHap300 BeadChip and an expanding installed base of BeadStations.
- Profitability Improvement: Net loss narrowed significantly to $0.1 million from $1.2 million in the prior year, despite increased operating expenses.
- Expense Increases:
- R&D Expenses: Increased 39% to $8.2 million, primarily due to development of acquired CyVera technology and the adoption of SFAS No. 123R (stock-based compensation).
- SG&A Expenses: Increased 101% to $12.1 million. Approximately $1.9 million of this increase is attributable to the adoption of SFAS No. 123R. Remaining increases were due to legal costs for the Affymetrix litigation ($1.8 million) and sales force expansion.
- Cash Flow: Operating cash flow turned positive ($2.4 million) compared to a use of cash ($3.3 million) in the prior year, largely due to non-cash stock compensation charges and increased accounts payable, offset by higher inventory and receivables.
Guidance, Outlook, Risks, and Unusual Items
- Accounting Change (SFAS No. 123R): The company adopted new stock-based compensation rules effective January 2, 2006, recording an incremental $3.1 million expense in Q1 2006. Management expects this to add $12.0 million to $15.0 million in expenses for the full fiscal year 2006.
- Outlook: Management expects product and service gross margins to range between 66% and 69% for fiscal 2006. They anticipate continued increases in R&D and SG&A expenses as they expand product lines and sales infrastructure. The company does not provide specific revenue guidance but notes that quarterly results may fluctuate.
- Legal Proceedings (Critical Risk):
- Affymetrix Litigation: Affymetrix alleges patent infringement regarding BeadArray products. Trial is scheduled for October 16, 2006. An adverse ruling could result in injunctions or significant damages.
- Dr. Anthony Czarnik: A former employee alleges inequitable conduct regarding patent inventorship. Motions to dismiss are pending.
- Investment Activity: In March 2006, Illumina invested approximately $3.0 million in a secured convertible debenture of Genizon BioSciences Inc. This transaction is considered "linked" to product sales, resulting in the deferral of approximately $2.8 million in revenue.
- Liquidity: As of April 2, 2006, the company had $49.0 million in cash and cash equivalents. Management believes current resources are sufficient to fund operations for the foreseeable future but may seek additional capital for strategic acquisitions or market conditions.
Key Facts for Investor Verification
- Impact of SFAS 123R: Verify the full-year impact of the new stock-based compensation accounting standard, which is expected to increase expenses by $12M-$15M in 2006.
- Affymetrix Litigation Status: Monitor the outcome of the claims construction hearing and the October 2006 trial, as an adverse ruling poses an existential threat to core product sales.
- Revenue Deferral: Confirm the treatment of the $2.8 million deferred revenue related to the Genizon BioSciences investment and how it will be recognized over time.
- Margin Compression: Assess whether the decline in gross margins (from 69% to 67%) is a temporary mix issue or a structural trend due to the Invitrogen collaboration and competitive pricing.
- Capital Expenditures: Verify the utilization of the $4.2 million spent on property and equipment to triple manufacturing capacity for BeadChips.